Literature DB >> 10369308

A novel mutation in the gene for the adult skeletal muscle sodium channel alpha-subunit (SCN4A) that causes paramyotonia congenita of von Eulenburg.

R Sasaki1, H Takano, K Kamakura, K Kaida, A Hirata, M Saito, H Tanaka, S Kuzuhara, S Tsuji.   

Abstract

BACKGROUND: Paramyotonia congenita (PMC) of von Eulenburg is an autosomal dominant muscular disease characterized by exercise- and cold-induced myotonia and weakness. To date, 18 missense mutations in the adult skeletal muscle sodium channel alpha-subunit (SCN4A) gene have been identified to cause a spectrum of muscular diseases, including PMC of von Eulenburg, PMC without cold paralysis, potassium-aggravating myotonia, and hyperkalemic periodic paralysis. However, no obvious correlations can be made between the location or nature of amino acid substitutions in SCN4A and its clinical phenotypes.
OBJECTIVE: To describe clinical and genetic features of a family with PMC of von Eulenburg.
RESULTS: A Japanese family with cold-induced myotonia and weakness was diagnosed as having PMC of von Eulenburg. This phenotype was identified to be caused by a novel mutation that substituted a glutamic acid residue for a highly conserved glycine residue in the fourth transmembrane segment (S4) of domain IV. This predicted a decrease in positive charge specific for the S4.
CONCLUSION: In addition to the G1456E identified in this study, 4 mutations that cause a decrease in positive charge in the S4/D4 are associated with the phenotype of PMC of von Eulenburg. This provides an important genotype-phenotype correlation in sodium channelopathies.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10369308     DOI: 10.1001/archneur.56.6.692

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  7 in total

Review 1.  Mutational consequences of aberrant ion channels in neurological disorders.

Authors:  Dhiraj Kumar; Rashmi K Ambasta; Pravir Kumar
Journal:  J Membr Biol       Date:  2014-08-14       Impact factor: 1.843

2.  Defective fast inactivation recovery of Nav 1.4 in congenital myasthenic syndrome.

Authors:  W David Arnold; Daniel H Feldman; Sandra Ramirez; Liuyuan He; Darine Kassar; Adam Quick; Tara L Klassen; Marian Lara; Joanna Nguyen; John T Kissel; Christoph Lossin; Ricardo A Maselli
Journal:  Ann Neurol       Date:  2015-03-27       Impact factor: 10.422

3.  Mechanisms underlying a life-threatening skeletal muscle Na+ channel disorder.

Authors:  Dina Simkin; Isabelle Léna; Pierre Landrieu; Laurence Lion-François; Damien Sternberg; Bertrand Fontaine; Saïd Bendahhou
Journal:  J Physiol       Date:  2011-04-26       Impact factor: 5.182

4.  Skeletal muscle na channel disorders.

Authors:  Dina Simkin; Saïd Bendahhou
Journal:  Front Pharmacol       Date:  2011-10-14       Impact factor: 5.810

5.  Novel mutations in human and mouse SCN4A implicate AMPK in myotonia and periodic paralysis.

Authors:  Silvia Corrochano; Roope Männikkö; Peter I Joyce; Philip McGoldrick; Jessica Wettstein; Glenda Lassi; Dipa L Raja Rayan; Gonzalo Blanco; Colin Quinn; Andrianos Liavas; Arimantas Lionikas; Neta Amior; James Dick; Estelle G Healy; Michelle Stewart; Sarah Carter; Marie Hutchinson; Liz Bentley; Pietro Fratta; Andrea Cortese; Roger Cox; Steve D M Brown; Valter Tucci; Henning Wackerhage; Anthony A Amato; Linda Greensmith; Martin Koltzenburg; Michael G Hanna; Abraham Acevedo-Arozena
Journal:  Brain       Date:  2014-10-27       Impact factor: 13.501

6.  Mechanism-specific assay design facilitates the discovery of Nav1.7-selective inhibitors.

Authors:  Tania Chernov-Rogan; Tianbo Li; Gang Lu; Henry Verschoof; Kuldip Khakh; Steven W Jones; Maureen H Beresini; Chang Liu; Daniel F Ortwine; Steven J McKerrall; David H Hackos; Daniel Sutherlin; Charles J Cohen; Jun Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-08       Impact factor: 11.205

7.  Voltage sensor charge loss accounts for most cases of hypokalemic periodic paralysis.

Authors:  E Matthews; R Labrum; M G Sweeney; R Sud; A Haworth; P F Chinnery; G Meola; S Schorge; D M Kullmann; M B Davis; M G Hanna
Journal:  Neurology       Date:  2008-12-31       Impact factor: 9.910

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.